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Abstract 
Introduction:  In this manuscript, we present an oncological case of hypertrophic osteoarthropathy 
(HOA) associated with endometrial cancer.  
Presentation of the case:  A 46 year-old woman with a history of endometrial cancer (ER+/PR+) 
presented with hemoptysis and severe diffuse muscle and joint pain, intractable to hydromorphone 
and non-steroidal-anti-inflammatories. She was diffusely tender to palpation, prominently in the 
bilateral lower extremities. Bone scintigraphy showed diffuse osteoblastic activity in all extremities, 
most prominent in the tibiae, concordant with HOA.  Patient was treated with zoledronic acid (ZA) 
and ketorolac, achieving adequate pain control.   
Conclusion:  HOA has been associated with multiple primary malignancies, as well as other 
medical conditions.  Its association with endometrial cancer has been rarely described in the 
literature.  The pathophysiology of this disorder is poorly understood.  More studies are needed to 
further enhance our understanding of this rare disease. 
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Introduction 
Hypertrophic Osteoarthropathy (HOA; aka Marie-Bamberger’s disease or hypertrophic 
pulmonary osteoarthropathy [HPO]) is a rare syndrome characterized by abnormal proliferation of the 
skin and osseous tissue at the distal extremities, digital clubbing, periostosis of long tubular bones, and 
arthralgias[1, 2].  There is a primary or idiopathic form[3-5], and a secondary form associated with 
multiple malignancies including, most commonly, pulmonary, nasopharyngeal, esophageal, gastric, 
pancreatic, mesothelioma, breast phyllodes, renal cell, melanoma, thymic, and Hodgkin’s 
lymphoma[6-14], as well as with other noncancerous medical conditions discussed later[6, 7, 15-26].  
To our knowledge, reports of HOA associated with endometrial cancer are lacking in the literature 
with only one case reported in 1982[27].  Here we present a case of HOA associated with endometrial 
cancer.   
Case presentation 
A 46 year-old Hispanic woman, Gravida 0 Para 0, with a history of Stage IVB endometrial 
cancer was transferred to our institution for evaluation of dyspnea, hemoptysis, and diffuse muscle and 
joint pain, eight-to-ten out of ten in intensity and not controlled with IV hydromorphone and naproxen 
at the previous hospital.  She reported a four month history of worsening dyspnea and productive 
cough with whitish-yellow sputum and intermittent bright-red blood.   
 She was diagnosed in 2007 with Stage IVB endometrial cancer, >90% estrogen and 70% 
progesterone receptors positive, and was treated with total abdominal hysterectomy and bilateral 
salpingo-oophorectomy, followed by four cycles of taxol, doxorubicin, and cisplatin.  Her cancer 
recurred in 2013, requiring debulking and six cycles of taxotere and paraplatin.  An ultrasound-guided 
microwave ablation of a lesion between the diaphragm and liver was performed in 2015.  Repeat 
biopsies of endometrium (i.e., between the liver and diaphragm), peritoneum, and multiple hilar lymph 
nodes were negative for malignancy.  The lesions in the endometrium and peritoneum showed benign 
fibromuscular tissue with focal inflammation and benign fibroconnective and fibroadipose tissue, 
respectively.  
Her family and social histories were non-contributory.  Her home medications were oral daily 
letrozole 2.5 mg, levothyroxine 25 mcg, and cholecalciferol 10,000 units.  Her physical examination 
was remarkable for clubbing of the hands and severe diffuse tenderness to palpation in all extremities.  
She was noted to have a fever of 100.5 degrees Fahrenheit on admission, otherwise remained afebrile 
with no signs of infection.  Laboratory values were relevant for normocytic anemia (i.e., hemoglobin 
10.9 g/dL) stable compared to prior values from an outside hospital, leukocytosis (i.e., white blood cell 
count 12.88 k/μL) with a neutrophil count 9.77 k/μL, alkaline phosphatase 145 units/L, CA 125 level 
140 units/mL (increased from prior value), and erythrocyte sedimentation rate 92 MM/HR.  CPK and 
TSH were within normal limits.   
A posterior-anterior and lateral chest x-ray showed a wedge-shaped segmental right lower lobe 
opacity.  Given this finding in the setting of worsening dyspnea and hemoptysis, a CT scan of chest 
and bronchoscopy were performed.  CT scan showed retropharyngeal, mediastinal and right hilar 
lymphadenopathy, right middle lobe subpleural nodule, a 5.2 cm ill-defined liver mass, and no 
evidence of pulmonary embolism.  The bronchoscopy did not show evidence of malignancy or source 
of bleeding with only inflammatory cells observed on cytology.  
Given the patient’s severe diffuse pain, a bone scintigraphy was performed, which revealed 
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diffuse increased periosteal osteoblastic activity within the upper and lower extremity cortices, most 
prominent within the bilateral tibiae, concordant with HOA (Fig. 1).  There was no evidence of central 
skeletal system foci of abnormal increased osteoblastic activity.   
 
 
Figure 1  Bone scintigraphy.  Findings of diffuse increased periosteal osteoblastic activity within the upper and 
lower extremity cortices bilaterally, which was most noticeable within the tibiae bilaterally.  These findings are 
consistent with hypertrophic osteoarthropathy.  No evidence of central skeletal system foci of abnormal 
increased osteoblastic activity was identified.  A. Anterior view.  B. Anterior view with increased radioactive 
tracer technetium-99m HDP.  C. Posterior view.  D. Posterior view with increased radioactive tracer. 
 A positron emission tomography (PET) CT scan was performed and compared to prior 
imaging.  It showed progression of metabolically active neoplastic disease within the liver, right 
proximal retroperitoneal, and mediastinal lymph nodes; and new metabolic activity within the right 
superior mediastinal lymph nodes.  No hypermetabolic lytic/blastic lesions were identified in the 
skeleton. 
Upon initial presentation, her severe pain was treated with morphine 15 mg orally every 12 
hours and oxycodone 5 mg orally every 6 hours; however, the pain persisted.  Once the patient was 
diagnosed with HOA, she was treated with a single dose of zoledronic acid (ZA) IV 4 mg and 
ketorolac 15 mg IV every 6 hours.  Her pain significantly improved after 48 hours of treatment, with a 
decrease in intensity to a three out of ten.  Also, given her initial fever, leukocytosis, and lung findings, 
she was treated with levofloxacin 750 mg orally every 24 hours for ten days.  She was discharged with 
naproxen 500 mg orally every 12 hours and methylprednisolone 4 mg Medrol dosepak for six days.   
While inpatient, she was evaluated by specialists from gynecology-oncology, gastrointestinal 
and thoracic surgery, who deemed her to be inoperable.  She was discharged to follow up with her 
local oncologist for further management, including starting systemic chemotherapy.   
Discussion 
HOA is a rare syndrome characterized by digital clubbing, periostosis of long tubular bones, 
and mild-to-severe arthralgias that typically involve the elbow, wrist, metacarpal, knee, and ankle 
joints[1, 2].  It can be classified as primary (a.k.a. pachydermoperiostosis) or secondary, the latter 
accounting for 95% of cases.  The primary form is a rare genetic condition, which typically presents 
with pachydermia in addition to clubbing and periostosis[3-5].   
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The secondary form has been associated with a wide range of medical conditions, where non-
small cell lung cancers (i.e., squamous cell or adenocarcinoma) predominate accounting for 80% of 
HOA cases[6, 7].  Pulmonary metastasis is a rare cause of HOA, but has been reported from primary 
tumors such as osteosarcoma, fibrosarcoma, nasopharyngeal, and uterine cancers[2, 28]. HOA has also 
been linked to other primary malignancies such as nasopharyngeal, esophageal, gastric, pancreatic, 
mesothelioma, breast phyllodes, renal cell, melanoma, thymic, Hodgkin’s lymphoma[6-14]. To our 
knowledge, only one case of HOA associated with endometrial cancer has been reported[27].  In 
addition, HOA has been described secondary to non-malignant conditions such as inflammatory bowel 
disease, rheumatic diseases, cyanotic congenital heart diseases[6, 7, 15-17], liver disease[18-21], and 
chronic infections associated with bacterial endocarditis, tuberculosis, cystic fibrosis, syphilis, 
vascular prothesis, and immune deficiency syndrome[6, 7, 22-26].   
Its pathogenesis remains to be elucidated.  Different hypothesis have been postulated related 
to circulating signals based on disease resolution after removal of the underlying causative agent (e.g., 
chemotherapy, tumor resection).  One hypothesis is the localized activation of platelet-endothelial cells, 
with subsequent release of fibroblast growth factors (e.g., platelet-derived growth factor [PDGF]).  
Produced by different cell types (i.e., macrophages, monocytes, smooth muscle cells, vascular 
endothelial cells), PDGF is involved in inflammation, wound healing, and angiogenesis[29]. PDGF 
was demonstrated to be overexpressed in HOA[30].  It was postulated this to be due to (1) disorders 
with right-to-left shunt enabling megakaryocytes to bypass the lungs’ circulation and enter the 
systemic circulation, fostering new bone development, edema, and vascular proliferation in the 
extremities via production of PDGF[1, 5]; (2) tumor release of PDGF[31]; and/or (3) illnesses 
associated with HOA stimulating PDGF development via inflammatory cytokines[32].   
Vascular-endothelial growth factor (VEGF) was also found abnormally elevated in secondary 
HOA associated with lung cancer[1], possibly as a consequence of its production by the tumor given 
that VEGF is predictably increased in a number of solid tumors[33]. Induced by hypoxia in the rapidly 
growing solid tumors, VEGF stimulates angiogenesis and vascular permeability[33-35]. VEGF has 
also been postulated to stimulate bone formation by mediating osteoclasts and osteoblasts function[36]. 
HOA treatment involves treating the underlying cause and/or supportive management.  
Nguyen et al. (2011), from a comprehensive systematic literature review of secondary HOA, reported 
effective treatments to incorporate primary therapies that resulted in symptom resolution, such as 
tumor resection, radiotherapy, chemotherapy, organ transplantation, antibiotics or other treatments for 
infection, and surgical correction of cyanotic heart disease.  They also reported supportive therapies 
when the underlying cause could not be targeted, which successfully led to symptom control.  These 
included vagotomy, adrenergic antagonist, bisphosphonates (i.e., pamidronate or zoledronic acid [ZA]), 
NSAID’s (e.g., ketorolac, indomethacin), octreotide, and EGFR inhibitors (i.e., gefetinib)[37]. 
Bisphosphonates have a high affinity for bone, where they inhibit osteoclast activity and bone 
resorption[38].  The effective use of pamidronate and ZA for pain control in HOA has been reported 
since 1997[2, 13, 24, 25, 39, 40].  ZA is a newer, more potent bisphosphonate in pre-clinical models of 
bone resorption, and was shown to have equal or higher efficacy to pamidronate in lytic and blastic 
disease[41, 42].  In a case of HOA associated with nasopharyngeal cancer, a single dose of 4 mg of ZA 
IV resulted in pain resolution and swelling reduction[2].  ZA is a nitrogen-containing bisphosphonate 
that selectively builds in areas of active bone remodeling by binding to hydroxyapatite crystals, and 
subsequently inhibit osteoclastic bone resorption and induce osteoclast apoptosis via inhibition of 
farnesyl diphosphate synthase.  Its selectivity for bone and not other tissues bestows this drug with a 
great safety profile and limited side effects[2, 43, 44].  ZA can also have anti-tumor effects by 
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inducing autophagy, apoptosis, and S phase arrest[45-47], and regulating gene expression mediating 
inhibition of proliferation, invasion, and angiogenesis[48].   
NSAID’s such as ketorolac and indomethacin were also shown to decrease pain in HOA[49, 
50].  Even though the pathogenesis of HOA is unknown, the use of NSAID’s relies on aforementioned 
findings elucidating prostaglandin-induced periostitis in neonates with congenital heart disease[17, 51-
53].  Others postulated the theory that COX2-derived PGE2 is involved in the pathogenesis of HOA 
given the effectiveness of COX2 inhibitors[54].  In our case, the use of ZA and ketorolac significantly 
improved pain control, which was intractable to high doses of opioids.  The patient was discharged to 
initiate systemic chemotherapy to further treat her HOA. 
Conclusion 
Most cases of HOA have been associated with several primary malignancies. However, its 
association with endometrial cancer has been poorly reported in the literature[27]. Herein in the 
current manuscript, we report a case of a HOA linked to this primary malignancy.  The pathogenesis, 
diagnosis, and treatment of this disease remain poorly elucidated, and more studies are needed to 
further enhance our understanding of it.  
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